Epstein-Barr virus: the mastermind of immune chaos

The Epstein-Barr virus (EBV) is a ubiquitous human pathogen linked to various diseases, including infectious mononucleosis and multiple types of cancer. To control and eliminate EBV, the host’s immune system deploys its most potent defenses, including pattern recognition receptors, Natural Killer cells, CD8+ and CD4+ T cells, among others. The interaction between EBV and the human immune system is complex and multifaceted. EBV employs a variety of strategies to evade detection and elimination by both the innate and adaptive immune systems. This demonstrates EBV’s mastery of navigating the complexities of the immunological landscape. Further investigation into these complex mechanisms is imperative to advance the development of enhanced therapeutic approaches with heightened efficacy. This review provides a comprehensive overview of various mechanisms known to date, employed by the EBV to elude the immune response, while establishing enduring latent infections or instigate its lytic replication.

[1]  K. Lin,et al.  Upregulation of IQGAP2 by EBV transactivator Rta and its influence on EBV life cycle , 2023, Journal of virology.

[2]  M. Blondel,et al.  The hide-and-seek game of the oncogenic epstein-barr virus-encoded EBNA1 protein with the immune system: An RNA G-quadruplex tale. , 2023, Biochimie.

[3]  E. Puchhammer-Stöckl,et al.  Inhibitory NKG2A+ and absent activating NKG2C+ NK cell responses are associated with the development of EBV+ lymphomas , 2023, Frontiers in Immunology.

[4]  Edward L. Huttlin,et al.  An Epstein-Barr virus protein interaction map reveals NLRP3 inflammasome evasion via MAVS UFMylation , 2023, Molecular cell.

[5]  Lijuan Yang,et al.  Genetic variability and mutation of Epstein‒Barr virus (EBV)-encoded LMP-1 and BHRF-1 genes in EBV-infected patients: identification of precise targets for development of personalized EBV vaccines , 2023, Virus Genes.

[6]  Haidi Yang,et al.  Epstein–Barr virus envelope glycoprotein 110 inhibits NF-κB activation by interacting with NF-κB subunit p65 , 2023, The Journal of biological chemistry.

[7]  E. Johannsen,et al.  EBV Reactivation from Latency Is a Degrading Experience for the Host , 2023, Viruses.

[8]  Kit-San Yuen,et al.  Suppression of cGAS- and RIG-I-mediated innate immune signaling by Epstein-Barr virus deubiquitinase BPLF1 , 2023, PLoS pathogens.

[9]  Wen Liu,et al.  Epstein‐Barr virus miR‐BART2‐5p and miR‐BART11‐5p regulate cell proliferation, apoptosis, and migration by targeting RB and p21 in gastric carcinoma , 2022, Journal of medical virology.

[10]  C. Wood,et al.  Regulation of B cell receptor signalling by Epstein–Barr virus nuclear antigens , 2022, The Biochemical journal.

[11]  M. Zeng,et al.  How EBV Infects: The Tropism and Underlying Molecular Mechanism for Viral Infection , 2022, Viruses.

[12]  M. Kazemian,et al.  EBV-associated diseases: Current therapeutics and emerging technologies , 2022, Frontiers in Immunology.

[13]  Yan Zhang,et al.  The lytic phase of Epstein–Barr virus plays an important role in tumorigenesis , 2022, Virus Genes.

[14]  S. Kenney,et al.  Epstein-Barr virus: Biology and clinical disease , 2022, Cell.

[15]  Jun Zhang,et al.  EBV Infection and Its Regulated Metabolic Reprogramming in Nasopharyngeal Tumorigenesis , 2022, Frontiers in Cellular and Infection Microbiology.

[16]  A. Myszka,et al.  Virus-Mediated Inhibition of Apoptosis in the Context of EBV-Associated Diseases: Molecular Mechanisms and Therapeutic Perspectives , 2022, International journal of molecular sciences.

[17]  Dongli Pan,et al.  MicroRNA Regulation of Human Herpesvirus Latency , 2022, Viruses.

[18]  Elif Naz Bingöl,et al.  How Epstein-Barr virus envelope glycoprotein gp350 tricks the CR2? A molecular dynamics study. , 2022, Journal of molecular graphics & modelling.

[19]  Z. Zeng,et al.  EBV miRNAs BART11 and BART17-3p promote immune escape through the enhancer-mediated transcription of PD-L1 , 2022, Nature communications.

[20]  Wen Liu,et al.  Epstein–Barr virus miR-BART4-3p regulates cell proliferation, apoptosis, and migration by targeting AXL in gastric carcinoma , 2022, Virus Genes.

[21]  Y. Zeng,et al.  EBV infection in epithelial malignancies induces resistance to antitumor natural killer cells via F3-mediated platelet aggregation. , 2022, Cancer research.

[22]  T. Wróbel,et al.  Toll-Like Receptors (TLRs), NOD-Like Receptors (NLRs), and RIG-I-Like Receptors (RLRs) in Innate Immunity. TLRs, NLRs, and RLRs Ligands as Immunotherapeutic Agents for Hematopoietic Diseases , 2021, International journal of molecular sciences.

[23]  A. Giordano,et al.  p53 signaling in cancer progression and therapy , 2021, Cancer cell international.

[24]  T. Murata,et al.  Molecular Basis of Epstein–Barr Virus Latency Establishment and Lytic Reactivation , 2021, Viruses.

[25]  W. Hammerschmidt,et al.  The Epstein-Barr Virus Oncogene EBNA1 Suppresses Natural Killer Cell Responses and Apoptosis Early after Infection of Peripheral B Cells , 2021, mBio.

[26]  M. Gaglia.  Anti-viral and pro-inflammatory functions of Toll-like receptors during gamma-herpesvirus infections , 2021, Virology journal.

[27]  John J Miles,et al.  Estimating the global burden of Epstein–Barr virus-related cancers , 2021, Journal of Cancer Research and Clinical Oncology.

[28]  Jiacheng Bi,et al.  Expression Regulation and Function of T-Bet in NK Cells , 2021, Frontiers in Immunology.

[29]  A. Pyle,et al.  The molecular mechanism of RIG‐I activation and signaling , 2021, Immunological reviews.

[30]  G. Khan,et al.  Epstein-Barr virus noncoding small RNA (EBER1) induces cell proliferation by up-regulating cellular mitochondrial activity and calcium influx. , 2021, Virus research.

[31]  Maria Malm,et al.  Serum and Tissue Level of TLR9 in EBV-Associated Oropharyngeal Cancer , 2021, Cancers.

[32]  K. Kono,et al.  Landscape of EBV-positive gastric cancer , 2021, Gastric Cancer.

[33]  X. Tao,et al.  Current Understanding of IL-37 in Human Health and Disease , 2021, Frontiers in Immunology.

[34]  C. Münz.  Immune Escape by Non-coding RNAs of the Epstein Barr Virus , 2021, Frontiers in Microbiology.

[35]  T. Kanda,et al.  RNAseq analysis identifies involvement of EBNA2 in PD-L1 induction during Epstein-Barr virus infection of primary B cells. , 2021, Virology.

[36]  S. Soltani,et al.  A review on EBV encoded and EBV-induced host microRNAs expression profile in different lymphoma types , 2021, Molecular Biology Reports.

[37]  C. Lim,et al.  The Role of NK Cells in EBV Infection and EBV-Associated NPC , 2021, Viruses.

[38]  Shitao Li,et al.  The Role of Ubiquitination in NF-κB Signaling during Virus Infection , 2021, Viruses.

[39]  R. Khanna,et al.  EBV and myeloid-derived suppressor cells. , 2021, Blood.

[40]  A. Bode,et al.  Targeting the signaling in Epstein–Barr virus-associated diseases: mechanism, regulation, and clinical study , 2021, Signal Transduction and Targeted Therapy.

[41]  P. Lieberman,et al.  Cell-cycle-dependent EBNA1-DNA crosslinking promotes replication termination at oriP and viral episome maintenance , 2021, Cell.

[42]  N. Trier,et al.  Epstein-Barr Virus and Systemic Autoimmune Diseases , 2021, Frontiers in Immunology.

[43]  A. Cascio,et al.  The Multifaced Role of STAT3 in Cancer and Its Implication for Anticancer Therapy , 2021, International journal of molecular sciences.

[44]  E. Flemington,et al.  EBV miRNAs are potent effectors of tumor cell transcriptome remodeling in promoting immune escape , 2020, bioRxiv.

[45]  W. Hammerschmidt,et al.  Multiple Viral microRNAs Regulate Interferon Release and Signaling Early during Infection with Epstein-Barr Virus , 2020, mBio.

[46]  M. V. Preciado,et al.  Macrophage's role in the microenvironmentgainst Epstein Barr Virus (EBV) in tonsils from pediatrics patients , 2020 .

[47]  C. Shannon-Lowe,et al.  Characterising EBV-associated lymphoproliferative diseases and the role of myeloid-derived suppressor cells. , 2020, Blood.

[48]  J. Preiksaitis,et al.  Using blood donors and solid organ transplant donors and recipients to estimate the seroprevalence of cytomegalovirus and Epstein-Barr virus in Canada: A cross-sectional study. , 2020, Journal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada.

[49]  Yingying Chen,et al.  Research Progress on NK Cell Receptors and Their Signaling Pathways , 2020, Mediators of inflammation.

[50]  N. Gálvez,et al.  The Role of Dendritic Cells During Infections Caused by Highly Prevalent Viruses , 2020, Frontiers in Immunology.

[51]  V. Maréchal,et al.  BHRF1, a BCL2 viral homolog, disturbs mitochondrial dynamics and stimulates mitophagy to dampen type I IFN induction , 2020, Autophagy.

[52]  Xueqiao Liu,et al.  Epstein-Barr Virus (EBV) Tegument Protein BGLF2 Suppresses Type I Interferon Signaling To Promote EBV Reactivation , 2020, Journal of Virology.

[53]  Wei Zhao,et al.  NLRP3 Inflammasome—A Key Player in Antiviral Responses , 2020, Frontiers in Immunology.

[54]  G. Giovannoni,et al.  Epidemiology of Epstein-Barr virus infection and infectious mononucleosis in the United Kingdom , 2020, BMC Public Health.

[55]  Sumita Bhaduri-McIntosh,et al.  STAT3 activates the anti-apoptotic form of caspase 9 in oncovirus-infected B lymphocytes. , 2020, Virology.

[56]  A. Strasser,et al.  EBV BCL-2 homologue BHRF1 drives chemoresistance and lymphomagenesis by inhibiting multiple cellular pro-apoptotic proteins , 2019, Cell Death & Differentiation.

[57]  Tao Chen,et al.  Epstein‐Barr virus tegument protein BGLF2 inhibits NF‐κB activity by preventing p65 Ser536 phosphorylation , 2019, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[58]  A. Jeong,et al.  Highlighted STAT3 as a potential drug target for cancer therapy , 2019, BMB reports.

[59]  Yuan He,et al.  The NLRP3 Inflammasome: An Overview of Mechanisms of Activation and Regulation , 2019, International journal of molecular sciences.

[60]  Kit-San Yuen,et al.  Epstein–Barr Virus and Innate Immunity: Friends or Foes? , 2019, Microorganisms.

[61]  H. Drexler,et al.  Epstein-Barr virus (EBV) activates NKL homeobox gene HLX in DLBCL , 2019, PloS one.

[62]  P. Mondon,et al.  Plasmacytoid dendritic cells respond to Epstein-Barr virus infection with a distinct type I interferon subtype profile. , 2019, Blood advances.

[63]  E. Munari,et al.  Human NK cells: surface receptors, inhibitory checkpoints, and translational applications , 2019, Cellular & Molecular Immunology.

[64]  K. Karimi,et al.  Myeloid Cells during Viral Infections and Inflammation , 2019, Viruses.

[65]  M. Cirone,et al.  EBV reduces autophagy, intracellular ROS and mitochondria to impair monocyte survival and differentiation , 2018, Autophagy.

[66]  E. Chakravarty,et al.  Epstein Barr Virus Interleukin 10 Suppresses Anti-inflammatory Phenotype in Human Monocytes , 2018, Front. Immunol..

[67]  Wenjun Liu,et al.  Latent Membrane Protein 1 of Epstein–Barr Virus Promotes RIG-I Degradation Mediated by Proteasome Pathway , 2018, Front. Immunol..

[68]  R. Cook,et al.  Harnessing RIG-I and intrinsic immunity in the tumor microenvironment for therapeutic cancer treatment , 2018, Oncotarget.

[69]  A. Carbone,et al.  Epstein Barr Virus-Associated Hodgkin Lymphoma , 2018, Cancers.

[70]  H. Favoreel,et al.  Herpesvirus Evasion of Natural Killer Cells , 2018, Journal of Virology.

[71]  V. Naumenko,et al.  Neutrophils in viral infection , 2018, Cell and Tissue Research.

[72]  B. Cullen,et al.  The Epstein-Barr virus miR-BHRF1 microRNAs regulate viral gene expression in cis. , 2017, Virology.

[73]  W. Xiong,et al.  Epstein-Barr Virus miR-BART6-3p Inhibits the RIG-I Pathway , 2017, Journal of Innate Immunity.

[74]  Yan Chen,et al.  An Epstein-Barr Virus MicroRNA Blocks Interleukin-1 (IL-1) Signaling by Targeting IL-1 Receptor 1 , 2017, Journal of Virology.

[75]  Jiang Li,et al.  LMP1-mediated glycolysis induces myeloid-derived suppressor cell expansion in nasopharyngeal carcinoma , 2017, PLoS pathogens.

[76]  W. Hammerschmidt,et al.  MicroRNAs of Epstein-Barr Virus Control Innate and Adaptive Antiviral Immunity , 2017, Journal of Virology.

[77]  Jianhong Lu,et al.  An update: Epstein-Barr virus and immune evasion via microRNA regulation , 2017, Virologica Sinica.

[78]  A. Letai,et al.  Epstein-Barr virus ensures B cell survival by uniquely modulating apoptosis at early and late times after infection , 2017, eLife.

[79]  Wei Zhang,et al.  BART miRNAs: an unimaginable force in the development of nasopharyngeal carcinoma , 2017, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[80]  C. Gysin,et al.  Tonsillar CD56brightNKG2A+ NK cells restrict primary Epstein-Barr virus infection in B cells via IFN-γ , 2016, Oncotarget.

[81]  W. Hammerschmidt,et al.  Epstein–Barr virus microRNAs reduce immune surveillance by virus-specific CD8+ T cells , 2016, Proceedings of the National Academy of Sciences.

[82]  W. Hammerschmidt,et al.  Epstein-Barr viral miRNAs inhibit antiviral CD4+ T cell responses targeting IL-12 and peptide processing , 2016, The Journal of experimental medicine.

[83]  C. Münz,et al.  NK Cell Influence on the Outcome of Primary Epstein–Barr Virus Infection , 2016, Front. Immunol..

[84]  J. Hannan.  The Structure-Function Relationships of Complement Receptor Type 2 (CR2; CD21). , 2016, Current protein & peptide science.

[85]  Jianji Pan,et al.  NF-κB Signaling Regulates Expression of Epstein-Barr Virus BART MicroRNAs and Long Noncoding RNAs in Nasopharyngeal Carcinoma , 2016, Journal of Virology.

[86]  H. Vrolijk,et al.  The Epstein-Barr Virus Glycoprotein gp150 Forms an Immune-Evasive Glycan Shield at the Surface of Infected Cells , 2016, PLoS pathogens.

[87]  H. Balfour,et al.  Cytokine-Mediated Loss of Blood Dendritic Cells During Epstein-Barr Virus-Associated Acute Infectious Mononucleosis: Implication for Immune Dysregulation. , 2015, The Journal of infectious diseases.

[88]  M. Rowe,et al.  Induction of the Lytic Cycle Sensitizes Epstein-Barr Virus-Infected B Cells to NK Cell Killing That Is Counteracted by Virus-Mediated NK Cell Evasion Mechanisms in the Late Lytic Cycle , 2015, Journal of Virology.

[89]  Yan Wang,et al.  Epstein-Barr Virus BZLF1-Mediated Downregulation of Proinflammatory Factors Is Essential for Optimal Lytic Viral Replication , 2015, Journal of Virology.

[90]  A. Moosmann,et al.  Latent Membrane Protein LMP2A Impairs Recognition of EBV-Infected Cells by CD8+ T Cells , 2015, PLoS pathogens.

[91]  Chung-Wu Lin,et al.  Epstein-Barr virus LMP2A suppresses MHC class II expression by regulating the B-cell transcription factors E47 and PU.1. , 2015, Blood.

[92]  M. Ressing,et al.  Silencing the shutoff protein of Epstein-Barr virus in productively infected B cells points to (innate) targets for immune evasion. , 2015, The Journal of general virology.

[93]  M. Fukayama,et al.  Profiling of Virus-Encoded MicroRNAs in Epstein-Barr Virus-Associated Gastric Carcinoma and Their Roles in Gastric Carcinogenesis , 2015, Journal of Virology.

[94]  W. Liang,et al.  EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy , 2014, Oncotarget.

[95]  C. Gysin,et al.  Role for early-differentiated natural killer cells in infectious mononucleosis. , 2014, Blood.

[96]  R. Franco,et al.  The role of EBV in the pathogenesis of Burkitt’s Lymphoma: an Italian hospital based survey , 2014, Infectious Agents and Cancer.

[97]  L. Hutt-Fletcher,et al.  Epstein-Barr Virus Glycoprotein gB and gHgL Can Mediate Fusion and Entry in trans, and Heat Can Act as a Partial Surrogate for gHgL and Trigger a Conformational Change in gB , 2014, Journal of Virology.

[98]  M. Rowe,et al.  Cooperation between Epstein-Barr Virus Immune Evasion Proteins Spreads Protection from CD8+ T Cell Recognition across All Three Phases of the Lytic Cycle , 2014, PLoS pathogens.

[99]  Steven G. E. Braem,et al.  Epstein-Barr Virus Large Tegument Protein BPLF1 Contributes to Innate Immune Evasion through Interference with Toll-Like Receptor Signaling , 2014, PLoS pathogens.

[100]  O. Boyman,et al.  Human natural killer cells prevent infectious mononucleosis features by targeting lytic Epstein-Barr virus infection. , 2013, Cell reports.

[101]  D. Nadal,et al.  A Distinct Subpopulation of Human NK Cells Restricts B Cell Transformation by EBV , 2013, The Journal of Immunology.

[102]  Ina Ersing,et al.  NF-κB and IRF7 Pathway Activation by Epstein-Barr Virus Latent Membrane Protein 1 , 2013, Viruses.

[103]  Chung-Wu Lin,et al.  Epstein-Barr virus-encoded miR-BART20-5p inhibits T-bet translation with secondary suppression of p53 in invasive nasal NK/T-cell lymphoma. , 2013, The American journal of pathology.

[104]  M. Ressing,et al.  EBV BILF1 Evolved To Downregulate Cell Surface Display of a Wide Range of HLA Class I Molecules through Their Cytoplasmic Tail , 2013, The Journal of Immunology.

[105]  T. Kanda,et al.  Epstein-Barr Virus Deubiquitinase Downregulates TRAF6-Mediated NF-κB Signaling during Productive Replication , 2013, Journal of Virology.

[106]  L. Frappier.  The Epstein-Barr Virus EBNA1 Protein , 2012, Scientifica.

[107]  N. Raab-Traub,et al.  Transcriptome Changes Induced by Epstein-Barr Virus LMP1 and LMP2A in Transgenic Lymphocytes and Lymphoma , 2012, mBio.

[108]  Chou-Wei Chang,et al.  Epstein-Barr Virus BGLF4 Kinase Downregulates NF-κB Transactivation through Phosphorylation of Coactivator UXT , 2012, Journal of Virology.

[109]  Z. Dong,et al.  Viral oncoprotein LMP1 disrupts p53-induced cell cycle arrest and apoptosis through modulating K63-linked ubiquitination of p53 , 2012, Cell cycle.

[110]  W. Hammerschmidt,et al.  The EBV Immunoevasins vIL-10 and BNLF2a Protect Newly Infected B Cells from Immune Recognition and Elimination , 2012, PLoS pathogens.

[111]  L. Frappier,et al.  Functions of the Epstein-Barr Virus EBNA1 Protein in Viral Reactivation and Lytic Infection , 2012, Journal of Virology.

[112]  M. Luftig,et al.  The role of microRNAs in Epstein-Barr virus latency and lytic reactivation. , 2011, Microbes and infection.

[113]  Adam Grundhoff,et al.  Virus-encoded microRNAs. , 2011, Virology.

[114]  R. Sosa,et al.  More than just a T-box: the role of T-bet as a possible biomarker and therapeutic target in autoimmune diseases. , 2011, Immunotherapy.

[115]  M. Ressing,et al.  EBV Lytic-Phase Protein BGLF5 Contributes to TLR9 Downregulation during Productive Infection , 2011, The Journal of Immunology.

[116]  H. Balfour,et al.  Progress and Problems in Understanding and Managing Primary Epstein-Barr Virus Infections , 2011, Clinical Microbiology Reviews.

[117]  M. Tommasino,et al.  EBV Latent Membrane Protein 1 Is a Negative Regulator of TLR9 , 2010, The Journal of Immunology.

[118]  P. Colman,et al.  Structural Basis for Apoptosis Inhibition by Epstein-Barr Virus BHRF1 , 2010, PLoS pathogens.

[119]  R. Fåhraeus,et al.  Epstein Barr Virus-Encoded EBNA1 Interference with MHC Class I Antigen Presentation Reveals a Close Correlation between mRNA Translation Initiation and Antigen Presentation , 2010, PLoS pathogens.

[120]  W. Hammerschmidt,et al.  Micro RNAs of Epstein-Barr Virus Promote Cell Cycle Progression and Prevent Apoptosis of Primary Human B Cells , 2010, PLoS pathogens.

[121]  M. Rola-Pleszczynski,et al.  Epstein-Barr Virus Interferes with the Amplification of IFNα Secretion by Activating Suppressor of Cytokine Signaling 3 in Primary Human Monocytes , 2010, PloS one.

[122]  Robert Valentine,et al.  Epstein-Barr virus-encoded EBNA1 inhibits the canonical NF-κB pathway in carcinoma cells by inhibiting IKK phosphorylation , 2010, Molecular Cancer.

[123]  Noam Stern-Ginossar,et al.  Diverse herpesvirus microRNAs target the stress-induced immune ligand MICB to escape recognition by natural killer cells. , 2009, Cell host & microbe.

[124]  Andrew I. Bell,et al.  An Epstein-Barr Virus Anti-Apoptotic Protein Constitutively Expressed in Transformed Cells and Implicated in Burkitt Lymphomagenesis: The Wp/BHRF1 Link , 2009, PLoS pathogens.

[125]  B. Shen,et al.  Down-Regulation of MHC Class II Expression through Inhibition of CIITA Transcription by Lytic Transactivator Zta during Epstein-Barr Virus Reactivation1 , 2009, The Journal of Immunology.

[126]  Chung-Pei Lee,et al.  Epstein-Barr Virus BGLF4 Kinase Suppresses the Interferon Regulatory Factor 3 Signaling Pathway , 2008, Journal of Virology.

[127]  M. Ressing,et al.  Epstein-Barr virus evasion of CD8(+) and CD4(+) T cell immunity via concerted actions of multiple gene products. , 2008, Seminars in cancer biology.

[128]  R. Fåhraeus,et al.  mRNA Translation Regulation by the Gly-Ala Repeat of Epstein-Barr Virus Nuclear Antigen 1 , 2008, Journal of Virology.

[129]  E. Johannsen,et al.  Epstein-Barr Virus LF2: an Antagonist to Type I Interferon , 2008, Journal of Virology.

[130]  L. Young,et al.  Epstein-Barr virus-encoded EBNA1 modulates the AP-1 transcription factor pathway in nasopharyngeal carcinoma cells and enhances angiogenesis in vitro. , 2008, The Journal of general virology.

[131]  Peter Parham,et al.  MHC class I-specific inhibitory receptors and their ligands structure diverse human NK-cell repertoires toward a balance of missing self-response. , 2008, Blood.

[132]  C. Croce,et al.  Epstein-Barr Virus-Induced miR-155 Attenuates NF-κB Signaling and Stabilizes Latent Virus Persistence , 2008, Journal of Virology.

[133]  E. Cesarman,et al.  EBV LMP2A affects LMP1-mediated NF-kappaB signaling and survival of lymphoma cells by regulating TRAF2 expression. , 2008, Blood.

[134]  Andrea J. O'Hara,et al.  EBV microRNAs in primary lymphomas and targeting of CXCL-11 by ebv-mir-BHRF1-3. , 2008, Cancer research.

[135]  A. Kieser,et al.  The Viral Oncoprotein LMP1 Exploits TRADD for Signaling by Masking Its Apoptotic Activity , 2008, PLoS biology.

[136]  T. Kanda,et al.  Epstein-Barr Virus (EBV)-Encoded RNA 2 (EBER2) but Not EBER1 Plays a Critical Role in EBV-Induced B-Cell Growth Transformation , 2007, Journal of Virology.

[137]  M. Ressing,et al.  A CD8+ T cell immune evasion protein specific to Epstein-Barr virus and its close relatives in Old World primates , 2007, The Journal of experimental medicine.

[138]  L. Hutt-Fletcher.  Epstein-Barr Virus Entry , 2007, Journal of Virology.

[139]  M. Ressing,et al.  Host shutoff during productive Epstein–Barr virus infection is mediated by BGLF5 and may contribute to immune evasion , 2007, Proceedings of the National Academy of Sciences.

[140]  L. Teyton,et al.  Interleukin-10 determines viral clearance or persistence in vivo , 2006, Nature Medicine.

[141]  Alexandra Schäfer,et al.  Epstein–Barr Virus MicroRNAs Are Evolutionarily Conserved and Differentially Expressed , 2006, PLoS pathogens.

[142]  Liming Wu,et al.  The C-terminal Activating Region 2 of the Epstein-Barr Virus-encoded Latent Membrane Protein 1 Activates NF-κB through TRAF6 and TAK1* , 2006, Journal of Biological Chemistry.

[143]  P. Stevenson,et al.  Gamma-Herpesvirus Latency Requires T Cell Evasion during Episome Maintenance , 2005, PLoS biology.

[144]  C. Sander,et al.  Identification of microRNAs of the herpesvirus family , 2005, Nature Methods.

[145]  J. Galon,et al.  Epstein-Barr virus nuclear antigen 2 induces interleukin-18 receptor expression in B cells. , 2005, Blood.

[146]  D. Thorley-Lawson,et al.  Terminal Differentiation into Plasma Cells Initiates the Replicative Cycle of Epstein-Barr Virus In Vivo , 2005, Journal of Virology.

[147]  J. Curnow,et al.  Epstein-Barr virus-encoded LMP2A regulates viral and cellular gene expression by modulation of the NF-kappaB transcription factor pathway. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[148]  R. Fåhraeus,et al.  Epstein-Barr virus: exploiting the immune system by interfering with defective ribosomal products. , 2004, Microbes and infection.

[149]  S. Kenney,et al.  BZLF1, an Epstein-Barr virus immediate-early protein, induces p65 nuclear translocation while inhibiting p65 transcriptional function. , 2004, Virology.

[150]  F. Martínez-Murillo,et al.  The Role of CTLs in Persistent Viral Infection: Cytolytic Gene Expression in CD8+ Lymphocytes Distinguishes between Individuals with a High or Low Proviral Load of Human T Cell Lymphotropic Virus Type 1 , 2004, The Journal of Immunology.

[151]  Shizuo Akira,et al.  Toll-like receptor signalling , 2004, Nature Reviews Immunology.

[152]  T. Schumacher,et al.  Interference with T cell receptor–HLA-DR interactions by Epstein–Barr virus gp42 results in reduced T helper cell recognition , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[153]  R. Fåhraeus,et al.  Self-Inhibition of Synthesis and Antigen Presentation by Epstein-Barr Virus-Encoded EBNA1 , 2003, Science.

[154]  A. Nanbo,et al.  Epstein–Barr virus RNA confers resistance to interferon‐α‐induced apoptosis in Burkitt's lymphoma , 2002 .

[155]  D. Thorley-Lawson,et al.  The expression pattern of Epstein-Barr virus latent genes in vivo is dependent upon the differentiation stage of the infected B cell. , 2000, Immunity.

[156]  J. Harton,et al.  Class II Transactivator: Mastering the Art of Major Histocompatibility Complex Expression , 2000, Molecular and Cellular Biology.

[157]  L. Flamand,et al.  EBV Suppresses Prostaglandin E2 Biosynthesis in Human Monocytes1 , 2000, The Journal of Immunology.

[158]  J. Yates,et al.  The Minimal Replicator of Epstein-Barr VirusoriP , 2000, Journal of Virology.

[159]  L. Flamand,et al.  Infection of Primary Human Monocytes by Epstein-Barr Virus , 2000, Journal of Virology.

[160]  L. Flamand,et al.  Epstein-Barr virus infects and induces apoptosis in human neutrophils. , 1998, Blood.

[161]  A Ciechanover,et al.  Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[162]  H. Kanegane,et al.  Viral interleukin-10 in chronic active Epstein-Barr virus infection. , 1997, The Journal of infectious diseases.

[163]  J. Hsieh,et al.  Truncated mammalian Notch1 activates CBF1/RBPJk-repressed genes by a mechanism resembling that of Epstein-Barr virus EBNA2 , 1996, Molecular and cellular biology.

[164]  A. Beaulieu,et al.  Epstein-Barr virus modulates de novo protein synthesis in human neutrophils. , 1995, Blood.

[165]  B. Sugden,et al.  An EBNA-1-dependent enhancer acts from a distance of 10 kilobase pairs to increase expression of the Epstein-Barr virus LMP gene , 1995, Journal of virology.

[166]  G. Chinnadurai,et al.  Epstein-Barr virus BHRF1 protein protects against cell death induced by DNA-damaging agents and heterologous viral infection. , 1994, Virology.

[167]  M. Rowe,et al.  Epstein-Barr virus-coded BHRF1 protein, a viral homologue of Bcl-2, protects human B cells from programmed cell death. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[168]  W. Bodmer.  The HLA system: structure and function. , 1987, Journal of clinical pathology.

[169]  E. Kieff,et al.  Epstein-barr virus gp350/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping, and endocytosis , 1987, Cell.

[170]  D. Reisman,et al.  A putative origin of replication of plasmids derived from Epstein-Barr virus is composed of two cis-acting components , 1985, Molecular and cellular biology.

[171]  J. Steitz,et al.  Two small RNAs encoded by Epstein-Barr virus and complexed with protein are precipitated by antibodies from patients with systemic lupus erythematosus. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[172]  L. Rymo.  Identification of transcribed regions of Epstein-Barr virus DNA in Burkitt lymphoma-derived cells , 1979, Journal of virology.

[173]  M. Epstein,et al.  VIRUS PARTICLES IN CULTURED LYMPHOBLASTS FROM BURKITT'S LYMPHOMA. , 1964, Lancet.

[174]  E. Robertson,et al.  Current Progress in EBV-Associated B-Cell Lymphomas. , 2017, Advances in experimental medicine and biology.

[175]  B. Cullen,et al.  EBV Noncoding RNAs. , 2015, Current topics in microbiology and immunology.

[176]  D. Thorley-Lawson.  EBV Persistence--Introducing the Virus. , 2015, Current topics in microbiology and immunology.

[177]  M. Rowe,et al.  Innate Immune Recognition of EBV. , 2015, Current topics in microbiology and immunology.

[178]  M. Ressing,et al.  Immune Evasion by Epstein-Barr Virus. , 2015, Current topics in microbiology and immunology.

[179]  R. Longnecker,et al.  Latent Membrane Protein 2 (LMP2). , 2015, Current topics in microbiology and immunology.

[180]  A. Kieser,et al.  The Latent Membrane Protein 1 (LMP1). , 2015, Current topics in microbiology and immunology.

[181]  Ying-ying Jin,et al.  Effects of Epstein-Barr virus on the development of dendritic cells derived from cord blood monocytes: an essential role for apoptosis. , 2012, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases.

[182]  R. Rochford.  Epidemiology of EBV Infection , 2009 .

[183]  Elliott Kieff,et al.  LMP1 TRAFficking activates growth and survival pathways. , 2007, Advances in experimental medicine and biology.

[184]  A. Kudoh,et al.  Latent and lytic Epstein‐Barr virus replication strategies , 2005, Reviews in medical virology.

[185]  P. Tak,et al.  NF-κB: a key role in inflammatory diseases , 2001 .

[186]  鳥居 哲夫.  Epstein-Barr virus latent membrane protein-1遺伝子の分子生物学的手法による解析 , 2000 .

[187]  C. Galperin.  Virus, provirus et cancer , 1994 .

[188]  J. Patterson.  Lymphomas. , 1992, Dermatologic clinics.

[189]  W J Macdonald,et al.  GASTRIC CARCINOMA. , 1912, Canadian Medical Association journal.